RxDoctor Payments Data

Sherman Tang, MD

Cardiovascular Disease · Sugar Land, TXNPI 1962455071

Payments from drug & device makers

$12,674in general payments, 2019–2025

Across 535 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$3K
  • Johnson & Johnson$1K
  • Novartis$1K
  • Amgen$838
  • Merck$757
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$585
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,536100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,674 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$228,691
Medicare patients
669
Services billed
2,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban422$386,486
XareltoRivaroxaban212$184,855
EntrestoSacubitril/Valsartan80$73,949
Repatha SureclickEvolocumab93$63,085
JardianceEmpagliflozin83$58,692
FarxigaDapagliflozin Propanediol74$55,892
VascepaIcosapent Ethyl22$15,087
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide377$11,659
NexlizetBempedoic Acid/Ezetimibe21$9,409
Nifedipine ErNifedipine301$7,907
Valsartan331$7,122
Nebivolol Hcl97$6,709
Metoprolol Succinate458$5,302
Midodrine Hcl30$4,377
Atorvastatin Calcium499$4,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$568$386,486422 claims
Johnson & JohnsonXarelto$1,136$184,855212 claims
NovartisEntresto$1,039$73,94980 claims
Boehringer IngelheimJardiance$3,432$58,69283 claims
AstraZenecaFarxiga$518$55,89274 claims
Esperion Therapeutics, Inc.Nexlizet$146$9,40921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →